Technology
Health
Biotechnology

BeiGene

$129.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.42 (-0.32%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell BeiGene and other stocks, options, ETFs, and crypto commission-free!

About BGNE

BeiGene, Ltd. American Depositary Shares, also called BeiGene, is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. Read More It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Employees
2,200
Headquarters
Beijing, Beijing
Founded
2010
Market Cap
7.74B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
225.37K
High Today
$132.75
Low Today
$127.65
Open Price
$130.00
Volume
175.04K
52 Week High
$194.56
52 Week Low
$105.19

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2016 IPO
China

BGNE Earnings

-$4.52
-$3.57
-$2.61
-$1.66
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.